Literature DB >> 12429039

Antibodies to pituitary surface antigens during various pituitary disease states.

Y M Keda1, I V Krjukova, I A Ilovaiskaia, M S Morozova, O V Fofanova, M B Babarina, E I Marova, Y A Pankov, V I Kandror.   

Abstract

Autoantibodies to cell surface antigens of human somatotropinoma (ASAS), human prolactinoma (ASAP) and rat adenohypophysis (ASARA) were assayed in the serum of patients with pituitary diseases associated with GH deficiency (GHD), such as pituitary dwarfism and primary empty sella syndrome (ESS), and in the serum of patients with hyperprolactinaemia of different etiologies: idiopathic hyperprolactinaemia, prolactinoma and ESS. The investigation was carried out with a cellular variant of an ELISA. Among children with GHD, the highest percentage of antibody-positive patients was found in the group with idiopathic isolated GHD (89% of ASAS(+) patients and 30% of ASARA(+) patients vs 33.3% and 0% respectively in the group with idiopathic combined pituitary hormone deficiency, and 33.3% and 9% in patients with pituitary hypoplasia associated with isolated GHD or combined pituitary hormone deficiency). Among hyperprolactinaemic patients, the highest ASAP and ASARA frequency was observed in patients with idiopathic hyperprolactinaemia (67.7% and 41.9% respectively) where it was twice as high as in the group of patients with prolactinoma. The proportion of ASAS(+) and ASARA(+) did not differ significantly between the groups of patients with ess with or without GHD. Similarly, there was no significant difference between the number of ESS ASAP(+) and ASARA(+) patients with or without hyperprolactinaemia. The data obtained suggested that autoimmune disorders may be primary, and responsible, at least in part, for pituitary dysfunction in the cases of idiopathic isolated GHD and idiopathic hyperprolactinaemia. At the same time, the autoimmune disorders in the patients with prolactinoma or ESS are probably secondary to the organic pituitary lesion and their significance in the development of the pituitary dysfunction is obscure.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12429039     DOI: 10.1677/joe.0.1750417

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  7 in total

1.  Prevalence of antipituitary antibodies in acromegaly.

Authors:  Federica Guaraldi; Patrizio Caturegli; Roberto Salvatori
Journal:  Pituitary       Date:  2012-12       Impact factor: 4.107

Review 2.  Prolactin and autoimmunity.

Authors:  Annamaria De Bellis; Antonio Bizzarro; Rosario Pivonello; Gaetano Lombardi; Antonio Bellastella
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

Review 3.  Pituitary autoimmune disease: nuances in clinical presentation.

Authors:  A Glezer; M D Bronstein
Journal:  Endocrine       Date:  2012-03-17       Impact factor: 3.633

4.  From pituitary expansion to empty sella: disease progression in a mouse model of autoimmune hypophysitis.

Authors:  Isabella Lupi; Jiangyang Zhang; Angelika Gutenberg; Melissa Landek-Salgado; Shey-Cherng Tzou; Susumu Mori; Patrizio Caturegli
Journal:  Endocrinology       Date:  2011-08-23       Impact factor: 4.736

5.  Pituitary autoimmunity is associated with hypopituitarism in patients with primary empty sella.

Authors:  I Lupi; L Manetti; V Raffaelli; L Grasso; C Sardella; M Cosottini; A Iannelli; M Gasperi; F Bogazzi; P Caturegli; E Martino
Journal:  J Endocrinol Invest       Date:  2011-05-27       Impact factor: 4.256

6.  Tumor infiltrating lymphocytes but not serum pituitary antibodies are associated with poor clinical outcome after surgery in patients with pituitary adenoma.

Authors:  Isabella Lupi; Luca Manetti; Patrizio Caturegli; Michele Menicagli; Mirco Cosottini; Aldo Iannelli; Giovanni Acerbi; Generoso Bevilacqua; Fausto Bogazzi; Enio Martino
Journal:  J Clin Endocrinol Metab       Date:  2009-10-29       Impact factor: 5.958

Review 7.  Pituitary autoimmunity: 30 years later.

Authors:  Patrizio Caturegli; Isabella Lupi; Melissa Landek-Salgado; Hiroaki Kimura; Noel R Rose
Journal:  Autoimmun Rev       Date:  2008-05-08       Impact factor: 9.754

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.